Esperion Therapeutics (ESPR) Cash & Equivalents (2012 - 2026)

Esperion Therapeutics has reported Cash & Equivalents for 15 years, with the latest figure at $156.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 36.22% year-over-year to $156.2 million; the trailing twelve-month figure through Mar 2026 stood at $156.2 million (up 36.22% YoY), and the FY2025 full-year result was $167.9 million, up 15.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $156.2 million, down from $167.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $226.6 million in Q1 2024, with the low at $82.2 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $138.9 million across 5 years, with a median of $144.7 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 76.01% — and 2025, when it plunged 54.54%.
• Esperion Therapeutics' Cash & Equivalents stood at $124.8 million in 2022, then tumbled by 34.08% to $82.2 million in 2023, then soared by 76.01% to $144.8 million in 2024, then increased by 15.95% to $167.9 million in 2025, then slipped by 6.97% to $156.2 million in 2026.
• The last three Cash & Equivalents figures came in at $156.2 million (Q1 2026), $167.9 million (Q4 2025), and $92.4 million (Q3 2025), per Business Quant data.